209 related articles for article (PubMed ID: 9160609)
1. Cardio-respiratory and other symptom clusters in panic disorder.
Bandelow B; Amering M; Benkert O; Marks I; Nardi AE; Osterheider M; Tannock C; Tremper J; Versiani M
Anxiety; 1996; 2(2):99-101. PubMed ID: 9160609
[No Abstract] [Full Text] [Related]
2. [Therapy of anxiety disorders from the behavior therapy viewpoint].
Meermann R
Z Arztl Fortbild (Jena); 1995 May; 89(2):115-25. PubMed ID: 7610676
[TBL] [Abstract][Full Text] [Related]
3. Respiratory panic disorder treatment with clonidine.
Valenca AM; Mezzasalma MA; Nascimento I; Lopes FL; Zin WA; Nardi AE
Can J Psychiatry; 2004 Feb; 49(2):154. PubMed ID: 15065755
[No Abstract] [Full Text] [Related]
4. [Panic disorder with agoraphobia].
Nordmann A
Praxis (Bern 1994); 1998 Feb; 87(6):217-9. PubMed ID: 9531817
[No Abstract] [Full Text] [Related]
5. Evidence for respiratory and nonrespiratory subtypes in panic disorder.
Abrams K; Rassovsky Y; Kushner MG
Depress Anxiety; 2006; 23(8):474-81. PubMed ID: 16841338
[TBL] [Abstract][Full Text] [Related]
6. Discordance between symptom and physiological criteria for the hyperventilation syndrome.
Spinhoven P; Onstein EJ; Sterk PJ; Le Haen-Versteijnen D
J Psychosom Res; 1993 Apr; 37(3):281-9. PubMed ID: 8478823
[TBL] [Abstract][Full Text] [Related]
7. Respiratory and other symptoms in panic disorder versus other anxiety disorders.
Ben-Amnon Y; Fux M; Maoz B; Benjamin J
Isr J Psychiatry Relat Sci; 1995; 32(1):38-43. PubMed ID: 7622345
[TBL] [Abstract][Full Text] [Related]
8. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA
Biol Psychiatry; 1996 Oct; 40(8):804-6. PubMed ID: 8894076
[No Abstract] [Full Text] [Related]
9. Panic disorder subtypes: further clinical differences.
Onur E; Alkin T; Tural U
Depress Anxiety; 2007; 24(7):479-86. PubMed ID: 17106872
[TBL] [Abstract][Full Text] [Related]
10. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
11. The symptom structure of panic disorder: a trial using factor and cluster analysis.
Shioiri T; Someya T; Murashita J; Takahashi S
Acta Psychiatr Scand; 1996 Feb; 93(2):80-6. PubMed ID: 8686487
[TBL] [Abstract][Full Text] [Related]
12. The development of agoraphobia in panic disorder: a predictable process?
Langs G; Quehenberger F; Fabisch K; Klug G; Fabisch H; Zapotoczky HG
J Affect Disord; 2000 Apr; 58(1):43-50. PubMed ID: 10760557
[TBL] [Abstract][Full Text] [Related]
13. Ondansetron in the treatment of panic disorder.
Schneier FR; Garfinkel R; Kennedy B; Campeas R; Fallon B; Marshall R; O'Donnell L; Hogan T; Liebowitz MR
Anxiety; 1996; 2(4):199-202. PubMed ID: 9160623
[No Abstract] [Full Text] [Related]
14. Further evaluation of the MMPI Pan scale in psychiatric and medical patients.
Henrichs TF; Beitman BD
J Clin Psychol; 1992 Mar; 48(2):211-5. PubMed ID: 1573021
[TBL] [Abstract][Full Text] [Related]
15. Language of dyspnea in panic disorder.
Perna G; Caldirola D; Namia C; Cucchi M; Vanni G; Bellodi L
Depress Anxiety; 2004; 20(1):32-8. PubMed ID: 15368594
[TBL] [Abstract][Full Text] [Related]
16. Personality dimensions in panic disorder before and after effective treatment.
Starcevic V; Uhlenhuth EH
Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
[No Abstract] [Full Text] [Related]
17. Gabapentin in somatoform and panic disorder.
Joos AA; Zeeck A
J Clin Psychopharmacol; 2013 Feb; 33(1):140-2. PubMed ID: 23288241
[No Abstract] [Full Text] [Related]
18. Social phobia with sudden onset--post-panic social phobia?
Kristensen AS; Mortensen EL; Mors O
J Anxiety Disord; 2008 May; 22(4):684-92. PubMed ID: 17728097
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
Kramer MS; Cutler NR; Ballenger JC; Patterson WM; Mendels J; Chenault A; Shrivastava R; Matzura-Wolfe D; Lines C; Reines S
Biol Psychiatry; 1995 Apr; 37(7):462-6. PubMed ID: 7786960
[TBL] [Abstract][Full Text] [Related]
20. Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
Sheehan DV; Raj AB; Harnett-Sheehan K; Dorotheo J; Sheehan MF; Trehan R; Knapp E; Swiontek A; Coleman B
Anxiety; 1996; 2(1):40-6. PubMed ID: 9160598
[No Abstract] [Full Text] [Related]
[Next] [New Search]
